GET DAILY SIGNALSWhy Is Biodesix (BDSX) Stock Down -51.11% Today?
Key Takeaways
- Biodesix (BDSX) shares plunged roughly 51.11% to about $9.70 from a prior close of $19.84.
- The primary catalyst was a third-quarter revenue miss coupled with a sharp cut to full-year guidance.
- Revenue grew 10% to $24.0 million but fell well short of the roughly $27.5 million Wall Street expected.
- Management slashed its 2026 revenue outlook to $101–$103 million from a prior $108–$114 million, citing sales-force shortfalls, seasonality, and project-timing delays.
- The stock had roughly tripled year to date before the report, leaving it vulnerable to a sharp growth-expectations reset.
- Traders are now watching fourth-quarter execution, sales-team rebuild progress, and analyst estimate revisions.
- Get deeper detail on Price Targets, Earnings, and Forecast for this ticker.
- Explore top-performing automated strategies in the Trending AI Robots section.
Opening Summary
Biodesix, Inc. (BDSX), a Louisville, Colorado-based diagnostics company that develops blood-based lung tests and provides development services to biopharmaceutical firms, is enduring one of its sharpest single-session selloffs on record. Shares tumbled roughly 51.11% in Friday trading, falling to about $9.70 from Thursday's closing price of $19.84. The decline was triggered by third-quarter results that missed revenue expectations and by a meaningful downward revision to the company's full-year outlook, breaking a beat-and-raise pattern that had underpinned a powerful year-to-date rally.
Q3 Results Break the Growth Narrative
The market reaction was driven primarily by an earnings-driven move that disappointed investors. Biodesix reported third-quarter revenue of $24.0 million, up 10% year over year but below the roughly $27.5 million consensus estimate. Diagnostic testing revenue rose 16% to about $23 million, while test volumes increased 24% to approximately 19,400. However, development services revenue declined to roughly $1 million from $1.9 million a year earlier, reflecting the timing of project completion and revenue recognition.
The net loss narrowed to $8.03 million, or $0.75 per share, from $8.72 million, or $1.16 per share, a year earlier. While the loss was largely in line with expectations, the top-line shortfall signaled a deceleration from the 40%-plus growth rates of earlier quarters, unsettling a shareholder base that had priced in sustained momentum.
Guidance Cut Reignites Execution Worries
Compounding the miss, management lowered its full-year 2026 revenue guidance to $101 million to $103 million, down from a prior range of $108 million to $114 million and below the roughly $110.5 million Wall Street had modeled. Chief Executive Scott Hutton attributed the shortfall to fewer contributing sales representatives than planned, greater-than-anticipated seasonality in primary care, and delays in external customer dependencies that postponed development-services revenue.
Hutton framed the issues as "largely related to execution and timing" rather than a change in demand or clinical utility, and pointed to early fourth-quarter signs of accelerating new physician acquisition. Yet the guidance reset — the midpoint now implies roughly 15% growth for the year versus about 25% previously — was enough to trigger a wave of selling, including analyst target adjustments such as TD Cowen lowering its price target to $34 from $40 while retaining a Buy rating.
Market Context and Trading Activity
The price action reflects a classic growth-expectations reset in a small-cap, momentum-driven name. Having roughly tripled year to date through Thursday's close, BDSX was especially sensitive to any break in its compounding story. Trading volume was sharply elevated relative to the stock's typical activity, indicating broad-based repositioning rather than isolated selling. The decline far outpaced broader healthcare and diagnostics peers, underscoring that this was a company-specific reaction to earnings and guidance rather than a sector-wide or macro-driven move. The stock's 52-week range of roughly $5.26 to $31.97 highlights both the magnitude of the prior run and the extent of the reversal.
What Comes Next for BDSX
Attention now shifts to whether management can deliver on its promised fourth-quarter re-acceleration. Key areas to watch include the rebuilding of the sales organization toward its year-end target, the trajectory of new physician acquisition, and whether development-services projects shift into 2027 as flagged on the earnings call. Investors will also monitor progress toward profitability, with the company continuing to target gross margins near 80% and gradual improvement toward adjusted EBITDA breakeven. Risks include ongoing execution uncertainty, competitive pressure on the sales force, and the possibility of further estimate revisions as analysts recalibrate their models to the reduced outlook.
Trending AI Robots
For traders seeking a more systematic approach to volatile small-cap names like BDSX, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing automated trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only those demonstrating superior performance under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving investors a range of algorithmic tools to explore. Consider reviewing the Trending AI Robots to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BDSX's RSI Indicator stays in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDSX advanced for three days, in 202 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
BDSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDSX as a result. In 78 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
BDSX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BDSX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BDSX entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.843) is normal, around the industry mean (67.298). P/E Ratio (-2.752) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.463) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. BDSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties